AVENUE THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
AVENUE THERAPEUTICS INC. - More news...
AVENUE THERAPEUTICS INC. - More news...
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
- Avenue Therapeutics to Participate in Upcoming Investor Conferences
- Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
- Avenue Therapeutics Announces Reverse Stock Split
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
- Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
- Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
- Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
- Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
- Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
- Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
- Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
- Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics to Present at Aegis Capital Virtual Conference
- Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
